Can ADMA Biologics cover its short-term obligations?

Its current ratio is 6.95 — current assets exceed current liabilities.

Where does ADMA Biologics's balance sheet data come from?

Every line is extracted from ADMA Biologics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

ADMA Biologics ADMA Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$138.15M+92.9%	$87.63M-15.0%	$61.39M-29.2%	$90.29M+2.3%	$71.63M+58.0%
Accounts receivable, net	$135.86M+36.7%	$158.43M+217%	$137.67M+175%	$109.73M+264%	$99.41M+100%
Inventories	$222.1M+29.0%	$206.47M+21.3%	$196.67M+14.5%	$191.46M+6.5%	$172.19M-3.1%
Raw materials	$89.28M+17.8%	$96.61M+59.8%	$87.84M+59.0%	$100.37M+76.1%	$75.82M+27.5%
Work in process	$67.53M+35.7%	$57.8M-6.2%	$44.48M-16.8%	$43.17M-21.6%	$49.78M+1.0%
Finished goods	$65.29M+40.1%	$52.06M+8.2%	$64.35M+2.0%	$47.92M-29.3%	$46.59M-32.5%
Prepaid expenses and other current assets	$15.06M+75.3%	$7.46M-7.1%	$6.93M-27.4%	$8.09M+46.4%	$8.59M+130%
Assets held for sale	——	——	——	——	——
Total current assets	$511.17M+45.3%	$466.51M+40.8%	$402.66M+26.5%	$399.56M+31.6%	$351.81M+27.3%
Property and equipment, net	$65.01M+12.6%	$65.06M+18.9%	$69.51M+29.5%	$57.5M+5.8%	$57.71M+4.3%
Accumulated depreciation	——	——	——	$37.52M+22.8%	$35.5M+23.9%
Operating lease right-of-use assets	$6.4M-20.2%	$6.65M-23.0%	$9.27M+4.2%	$8.96M-2.1%	$8.02M-14.7%
Goodwill	$3.53M0.0%	$3.53M0.0%	$3.53M0.0%	$3.53M0.0%	$3.53M0.0%
Intangible assets, net	$630K+39.4%	$632K+37.4%	$491K+1.2%	$527K+10.0%	$452K+40.8%
Deferred tax assets	$296.9M+256%	$307.78M+12,099%	$237.05M—	$162.61M—	$83.38M—
Allowance for credit losses	——	——	——	——	——
Total assets	$665.18M+30.3%	$624.24M+27.7%	$568.69M+45.6%	$558.38M+48.3%	$510.57M+45.5%
Accounts payable	$20.52M-0.4%	$22.52M+11.4%	$24.02M+49.9%	$29.77M+110%	$20.61M+19.9%
Accrued expenses	$48.56M+53.9%	$40.47M+18.7%	$28.83M+4.7%	$43.9M+58.3%	$31.56M-6.3%
Accrued compensation	$5.45M+183%	$809K-75.7%	$2.76M+37.5%	$3.43M+5.4%	$1.92M+3.8%
Deferred revenue	$1.37M+857%	$1.41M+883%	$1.44M+907%	$143K-87.3%	$143K-87.2%
Current portion of long-term debt	——	——	——	——	——
Operating lease liabilities, current	$1.18M-1.0%	$1.1M-10.0%	$1.3M+8.8%	$1.13M-1.3%	$1.19M+8.7%
Liabilities held for sale	——	——	——	——	——
Income taxes payable	$17.12M—	$8.62M—	$2.79M—	——	——
Accrued interest	$750K-60.4%	$172K-94.0%	$105K-97.0%	$1.27M—	$1.89M—
Total current liabilities	$73.54M+37.5%	$69.54M+25.2%	$56.49M+25.8%	$74.94M+69.6%	$53.5M+0.8%
Deferred tax liabilities	——	——	——	——	——
Long-term debt	——	——	——	——	——
Operating lease liabilities, non-current	$6.37M-23.3%	$6.65M-22.4%	$9.4M+6.0%	$9.3M+1.3%	$8.3M-12.5%
Total liabilities	$274.86M+100%	$146.92M+5.2%	$137.5M-13.4%	$160.06M-14.9%	$137.15M-30.4%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	300M0.0%	300M0.0%	300M0.0%	300M0.0%	300M0.0%
Additional paid-in capital	$649.8M-0.8%	$671.04M+2.0%	$665.38M+2.0%	$660.91M+2.5%	$655.07M+2.0%
Retained earnings	-$116.33M+58.7%	-$161.65M+47.6%	-$211.03M+49.8%	-$247.46M+45.8%	-$281.68M+42.3%
Treasury stock	$143.17M—	——	——	——	——
Total stockholders' equity	$390.33M+4.5%	$477.32M+36.8%	$431.19M+85.9%	$398.33M+112%	$373.42M+143%
Total liabilities and stockholders' equity	$665.18M+30.3%	$624.24M+27.7%	$568.69M+45.6%	$558.38M+48.3%	$510.57M+45.5%
Contract Assets, Net	——	——	——	——	——
Disposal Group - Other Current Assets	——	——	——	——	——
Other Inventory, Net	——	——	——	——	——
Net Investment in Lease	$6.4M-20.2%	$6.65M-23.0%	$9.27M+4.2%	$8.96M-2.1%	$8.02M-14.7%
Net Operating Loss Carryforwards	——	——	——	——	——
Deferred tax assets	$69.97M—	$73.26M—	$74.43M—	——	——
Other intangible assets—net	$630K+39.4%	$632K+37.4%	$491K+1.2%	$527K+10.0%	$452K+40.8%
Operating lease right-of-use assets	$6.4M-20.2%	$6.65M-23.0%	$9.27M+4.2%	$8.96M-2.1%	$8.02M-14.7%
Property, plant and equipment at cost	——	——	——	$95.02M+12.0%	$93.21M+11.0%
Operating Lease Right-of-Use Assets in Other Assets	$6.4M-20.2%	$6.65M-23.0%	$9.27M+4.2%	$8.96M-2.1%	$8.02M-14.7%
Operating Lease Liability Payments - 2024 (Lessee)	$1.95M—	$1.95M—	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	$1.9M—	$1.9M—	——	——	——
Lease Liability Payments - Due Year Two	$1.95M—	$1.95M—	——	——	——
Lease Liability Payments - Due Year Three	$1.97M—	$1.97M—	——	——	——
Lease Liability Payments - Due Year Four	$1.9M—	$1.9M—	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	$1.55M—	$1.99M—	——	——	——
Operating Lease Liability Payments Due	$10.38M—	$10.82M—	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	$2.84M—	$3.07M—	——	——	——
Professional Service Fees Payable	$12.6M+4.0%	$14.81M+28.0%	$10.68M+9.2%	$11.39M+36.0%	$12.12M+70.6%
Debt Maturity - 2024	——	——	——	——	——
Debt Maturity - 2027	——	——	——	——	——
Operating Lease Liability Payments - 2026 (Lessee)	$1.97M—	$1.97M—	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	$1.56M—	$1.56M—	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	$1.9M—	$1.9M—	——	——	——
Operating Lease Liability Payments - 2029 (Lessee)	$1.56M—	$1.56M—	——	——	——
Lease Liability Payments - Due After Year Five	——	——	——	——	——
Operating Lease Liability Payments - Thereafter (Lessee)	——	——	——	——	——
Accrued expenses and other liabilities	$48.56M+53.9%	$40.47M+18.7%	$28.83M+4.7%	$43.9M+58.3%	$31.56M-6.3%
Deferred income	$1.37M-9.5%	$1.41M-9.2%	$1.44M-9.0%	$1.48M-8.8%	$1.51M-8.6%
Total debt	$204.41M+2,055%	$79.89M-2.7%	$83.12M+726%	$10.43M+1.0%	$9.49M-10.3%
Total Carrying Value of Debt	——	——	——	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Authorized	——	——	——	——	——
Common Stock Shares Issued	241M+27,715%	239.8M+1.3%	239.7M+1.4%	239.4M+2.7%	866.3K-56.2%
Common Stock Shares Outstanding	——	——	——	——	——
Convertible Preferred Stock Authorized Shares	10M0.0%	10M0.0%	10M0.0%	10M0.0%	10M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$24K0.0%	$24K0.0%	$24K0.0%	$24K+4.3%	$24K+4.3%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Treasury Stock, Value	$143.17M—	——	——	——	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share Repurchase Authorization Limit	——	——	——	——	——
Shares Reserved for Future Issuance Under Stock Plans	——	——	——	——	——
Cumulative Cost Basis	——	——	——	$95.02M+12.0%	$93.21M+11.0%
Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts	$200K-93.3%	$300K+50.0%	$300K+50.0%	$200K0.0%	$3M+1,400%
Accrued bonuses	$1.74M+3.9%	$6.01M+1.9%	$4.51M+23.0%	$3.07M+28.9%	$1.67M+37.0%
Professional service fees	$12.6M+4.0%	$14.81M+28.0%	$10.68M+9.2%	$11.39M+36.0%	$12.12M+70.6%
Accrued Rebates Current	$7.16M+47.7%	$5.76M+38.6%	$5.12M+8.1%	$4.17M-3.8%	$4.85M-72.0%
Accrued Testing Current	$389K-16.0%	$130K-84.3%	$301K-48.0%	$389K-20.3%	$463K+40.7%
Common stock, capital shares reserved for future issuance	——	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$300M0.0%	$300M0.0%	$300M0.0%	$300M0.0%	$300M0.0%
Common stock, shares issued (in shares)	$240.96M+27,715%	$239.79M+1.3%	$239.66M+1.4%	$239.38M+2.7%	$866.3K-56.2%
Common Stock, Shares, Outstanding	$232.29M-2.6%	$237.87M+0.5%	$238.33M+0.8%	$238.57M+2.4%	$238.53M+2.9%
Long-term debt, gross	——	——	——	——	——
Deferred Tax Liabilities, Gross	——	——	——	——	——
Disallowed business interest expense carryforward	——	——	——	——	——
Deferred Tax Assets Lease Obligations	——	——	——	——	——
Deferred Tax Assets, Net	——	——	——	——	——
Deferred Tax Assets, Net of Valuation Allowance	——	——	——	——	——
U.S. federal, state and foreign net operating loss, credit carryforwards and other carryforwards	——	——	——	——	——
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost	——	——	——	——	——
Temporary differences related to Texas Margin Tax	——	——	——	——	——
Deferred Tax Liabilities Depreciation Of Property And Equipment	——	——	——	——	——
Deferred Tax Liabilities, Other	——	——	——	——	——
Deferred Tax Liabilities Right Of Use Asset	——	——	——	——	——
Deposits And Other Noncurrent Assets	$8.47M+3.4%	$8.6M+52.0%	$8.8M+51.2%	$9.06M+73.6%	$8.19M+39.0%
Disposal Group Including Discontinued Operation Lease Liabilities Current	——	——	——	——	——
Disposal Group Including Discontinued Operation Property Plant And Equipment Current	——	——	——	——	——
Disposal Group Including Discontinued Operation Rightof Use Assets Current	——	——	——	——	——
Raw materials	$89.28M+17.8%	$96.61M+59.8%	$87.84M+59.0%	$100.37M+76.1%	$75.82M+27.5%
Lessee Operating Lease Liability Payments Due	$10.38M—	$10.82M—	——	——	——
Lessee Operating Lease Liability Payments Due After Year Six	——	——	——	——	——
Lessee Operating Lease Liability Payments Due Year Six	——	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	$2.84M—	$3.07M—	——	——	——
2028	——	——	——	——	——
2029	——	——	——	——	——
2030	——	——	——	——	——
2027	——	——	——	——	——
Remainder of 2026	——	——	——	——	——
Operating And Financing Lease Liability	$7.5M-2.6%	$7.7M-21.4%	$10.7M+5.9%	$10.4M+1.0%	$7.7M-27.4%
Operating Lease Weighted Average Discount Rate Percent	——	——	——	——	——
Other accrued liabilities	$3.35M+63.8%	$4.17M+109%	$2.56M-22.7%	$17.49M+663%	$2.05M-14.1%
Preferred stock, capital shares reserved for future issuance (in shares)	10M0.0%	10M0.0%	10M0.0%	10M0.0%	10M0.0%
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	——	——	——	——	——
Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	——	——	——	——	——
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1	——	——	——	——	——
Shares, Issued	——	——	——	——	——
Share Repurchase Program, Authorized, Amount	——	——	——	——	——
Treasury stock, shares (in shares)	$8.67M—	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can ADMA Biologics cover its short-term obligations?: Its current ratio is 6.95 — current assets exceed current liabilities.
Where does ADMA Biologics's balance sheet data come from?: Every line is extracted from ADMA Biologics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.